Background: There is in vitro evidence that T cells from allergic patients react to
| INTRODUCTION
Penicillins are considered the drugs most frequently eliciting allergic reactions. 1, 2 Patients commonly complain of various and heterogeneous symptoms ranging from immediate skin rash, respiratory symptoms, and anaphylaxis, to more delayed reactions such as bullous skin eruptions. 3 The mechanisms of immediate reactions to penicillins are mediated by specific IgE antibodies and penicillin-specific CD4 + T cells. 3 Spontaneous protein modification by the reactive form of the drug is an important process in adverse drug reactions. 4 In this process, drugs or haptens bind covalently to protein to form a complex of a sufficient size to trigger an immune response (haptenation). [5] [6] [7] This structure can later be processed by antigen presenting cells, 4 such as dendritic cells (DCs), and the resulting haptenated peptides exposed through major histocompatibility complex (MHC) class I or class II-dependent pathways are presented to T-cell receptors (TCRs). The specific amino acid sequence of peptides determines MHC allele specificity and the nature of the response. 8, 9 Alternative mechanisms imply the covalent or non-covalent binding (P-i concept)
of the drug to the peptides already exposed on the MHC. 10, 11 From a chemical point of view, the reactivity of penicillins depends on the b-lactam ring electrophilic character which suffers a nucleophilic attack by the amino groups of the lateral chains of lysine residues, resulting in the opening of the b-lactam structure. 12 Early works on the detection and identification of b-lactam-protein adducts allowed the identification of several proteins targeted by penicillins including human serum albumin (HSA), transferrin, and immunoglobulins. 1, 13 Penicillin-binding sites on HSA have been found both in vivo using sera obtained from patients and in vitro by synthesizing bioconjugates all of which mapped at lysine residues. 1, [14] [15] [16] We have recently used a combination of immunological and high-resolution MS (mass spectrometry) approaches to identify benzylpenicillin (BP)-binding sites on HSA. 17 There is in vitro evidence that T cells from allergic patients react with BP-HSA biocojugates. 12 Our group has recently shown the existence of na€ ıve CD4 + T cells specific for BP-HSA in healthy donors. 18 Moreover, activation of T cell clones from allergic patients may occur selectively in response to free drug or to drug conjugates. 1, 19 This latter observation raises the hypothesis that not only the drug, but also parts of the haptenated protein or peptides coupled to the drug may constitute the important structural determinants for antigen recognition by the TCR.
In this context, we were interested in defining candidate haptenated peptides from circulating proteins that are able to immunize patients to BP leading to hypersensitivity reactions. HSA is a good candidate for BP haptenization since BP-HSA conjugates have been identified in allergic patients. We selected candidate peptides using an in silico approach addressing peptide binding to HLA molecules.
BP-haptenated peptides were synthesized using an original BP-lysine monomer. 17 With the selected haptenated peptides, we were able to define BP-haptenated peptides recognized by na€ ıve T cells. BP-HSA and BP-haptenated peptides were then tested in penicillin-allergic patients showing significant specific lymphocyte proliferation to BP-HSA and to the selected BP-haptenated peptides previously found positive with na€ ıve T cells.
| METHODS

| Synthesis of benzylpenicillin-human serum albumin
BP-HSA was produced as described previously. 18, 19 The presence of BP on HSA was confirmed using Western blots and mass spectrometry MALDI-TOF analysis and is published in a companion work.
17
BP-binding sites on HSA were identified through tryptic digestion of BP-HSA bioconjugates followed by MALDI-MS and nano-LC-MS/MS analysis. 
| Benzylpenicillin-haptenated peptides
| Measurement of IgE antibodies specific to benzylpenicillin
Sera from the healthy donors were aliquoted and stored at À80°C.
Specific IgE directed against BP was quantified using a fluorescence enzyme immunoassay (ImmunoCAP, Thermo Fisher Scientific) as previously described. 23 Limit of quantification for IgE was 0.1 kU/L. IgE levels of donors are in Data S2.
| HLA-DR genotyping of healthy donors
PBMCs from healthy donors were isolated by density centrifugation on Ficoll-Hyperpaque gradients (Sigma-Aldrich Darmstadt, Germany), and DNA was extracted using the NucleoSpin Blood L kit (MachereyNagel, D€ uren, Germany) as described by the manufacturer protocol.
HLA-DR genotyping was performed using the All Set Gold SSP DRB1 typing kit (Invitrogen, Cergy, France), according to the manufacturer protocol. The HLA-DR genotype of donors is shown in Data S2.
| Benzylpenicillin-haptenated peptides HLAclass II binding ELISA assay
Binding to HLA-DR molecules was assessed by a competitive ELISA as previously described. 24 The competition for the immunopurified HLA class II molecules was performed between a reporter peptide (biotinylated) and the peptide to be tested. 24 Unlabeled forms of the reporter peptides were used as reference peptides to assess the quality of each experiment. The relative binding affinity reported was the ratio of the IC50 of the peptide to the IC50 of the reference peptide.
| Lymphocyte transformation test
PBMCs from subjects with a history of allergy to penicillins and in vivo screened by skin prick tests were isolated by Lymphoprep (Oslo, Norway). 
| Statistics
CD4 + T-cells frequency was estimated using the Poisson distribution according to the following formula:
To calculate statistical significance between stimulated and control conditions in allergic patients, triplicate values were compared between groups using a paired t test. Tests were performed using GraphPad Prism software â (version 5.0, year, La Jolla, CA, USA). Statistical tests (two-tailed) giving a P value smaller than .05 were considered statistically significant.
| RESULTS
| Detection and quantification of the frequency of blood-circulating CD4 + T cells recognizing benzylpenicillin-human serum albumin conjugates
The overall results showed that CD4 + T cells recognizing specifically BP-HSA were detected for all the tested donors, except donor 982, We then assessed whether BP-HSA recognizing CD4 + T cells involved in the immune response were na€ ıve, as previously shown. 18 Na€ ıve CD4 + T cells characterized by the expression of CD45RA were isolated from the PBMCs of 8 donors. BP-HSA CD4 + CD45RA + and KLH CD4 + CD45RA + T-cell lines were generated using the same methodology as described above. Results from the 8 tested donors
with BP-HSA showed that CD4 + CD45RA + T-cell lines specific for BP-HSA were detected in 7 donors among the 8 tested (Fig. 1B) .
Only one donor (number 966) was negative. However, this donor showed only one positive T-cell line when using total CD4+ T cells.
This discrepancy was probably due to the variability existing between the 2 experiments considering the low number of cell lines.
The frequency of BP-HSA-specific na€ ıve CD4 + T cells was then calculated for each donor tested using the Poisson distribution (Fig. 1B) . (Table 1 ; Data S3). These 3 peptides had the BP bound on lysines 159, 212, and 525 from HSA, respectively (Table 1) .
Finally, we assessed the dose-response of PT-BP using specific T-cell lines isolated from 2 different donors. T-cell lines responded to a peptide concentration of less 0.1 lg/mL for one donor and less 0.01 lg/mL for the second donor (Fig. 3 ).
| Role of HLA class II in the T-cell response to benzylpenicillin-haptenated peptides
To determine whether the T-cell response to BP-haptenated peptides was mediated by HLA class II, we tested the capacity of antibodies specific for HLA-DRa, HLA-DP, and HLA-DQ molecules to inhibit the activation of BP-haptenated peptide-specific T-cell lines when stimulated with BP-haptenated peptides. In total, 15 T-cell lines from 3 donors were tested with 6 BP-haptenated peptides (Data S4). Our 
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Peptide annotation results showed that T-cell responses to BP-haptenated peptides were dependent on more than one HLA class II molecule.
| In vitro CD4
+ T-cell response to benzylpenicillin-human serum albumin conjugates supported by multiple CD4 + T-cell epitopes
To identify CD4 + T-cell epitopes from BP-HSA, we derived CD4 + Tcell lines specific for BP-HSA from 2 healthy donors with different HLA-DR alleles using a T-cell assay as described previously. 28 Purified CD4 + T cells were seeded in multiple wells and stimulated weekly by autologous DCs previously loaded with BP-HSA to enrich the co-cultures in Ag-specific CD4 + T cells. After 3 rounds of stimulation, each independent T-cell line (CD4 + T cells present in a single well) was evaluated for its specificity using IFN-c ELISpot. The fine specificity of the BP-HSA-specific T-cell lines for BP-haptenated peptides was then evaluated in a second ELISpot assay using 4 BPhaptenated peptides to identify the haptenated peptides recognized by BP-HSA-specific T-cell lines. As an example, the T-cell line number 24 from donor PM65 was specific for peptides FS-BP and KV-BP, whereas the T-cell line number 9 from the second donor PM66
was specific only for one peptide, namely PT-BP (Fig. 4A ). On the other hand, we also investigated the specificity of BP-haptenated peptide-induced T-cell lines from a single donor toward BP-HSA (or HSA, as control). Four PT-BP-specific T-cell lines were reactive against BP-HSA (Fig. 4B ).
| Relative binding affinity of benzylpenicillinhaptenated and non-haptenated peptides to HLA class II molecules
We then evaluated the capacity of these peptides to bind to 10 HLA-DR molecules that are common alleles in the Caucasian population. We found that non-haptenated peptides LF and FS bound to 7 different HLA-DR molecules. Peptide PT also exhibited a broad specificity for HLA-DR molecules by binding strongly to 6 alleles. 
| Benzylpenicillin-haptenated peptides and benzylpenicillin-haptenated human serum albumin stimulated PBMCs from penicillin allergic patients
We then asked whether BP-HSA and BP-haptenated peptides were able to directly stimulate PBMCs from patients allergic to penicillin showed the highest frequency of positivity in the tested donors with BP bound on lysines 159, 525, and 212, respectively. These peptides were correctly identified using the IEDB in silico approach with BP facing the TCR and not facing the HLA class II molecule. Thus, we will refer these peptides as immunodominant. [33] [34] [35] We then tested whether these 3 immunodominant BP-hapte- to activate T cells using a Lys 541 peptide. 36 These results suggested that a threshold level of drug-protein adduct was exceeded in all patients exposed to a therapeutic drug course and a large proportion of patients were at risk to be "immunized" to beta-lactams. Since our results obtained using cells from na€ ıve subjects suggested that most individuals have a T-cell repertoire that can be activated with BP-haptenated peptides, we believe that the propensity to be "immunized" and then to develop hypersensitivity may be due to an imbalance in the immune regulation. Concerning, the possibility of an "immunized" patient to develop hypersensitivity, we can hypothesize that the imbalance between specific effector and regulatory T cells is needed in addition to the homing of these effector cells to target organs. More work is needed to identify whether putative epitope that could drive a Treg response do exist (Tregitopes) or whether the T effector/Treg response is mainly driven by the DC microenvironment through differential regulation of co-stimulatory/ co-inhibitory signals. Firenze) for providing blood samples from allergic patients and Mrs.
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